BR112016000658A2 - pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática - Google Patents

pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática

Info

Publication number
BR112016000658A2
BR112016000658A2 BR112016000658A BR112016000658A BR112016000658A2 BR 112016000658 A2 BR112016000658 A2 BR 112016000658A2 BR 112016000658 A BR112016000658 A BR 112016000658A BR 112016000658 A BR112016000658 A BR 112016000658A BR 112016000658 A2 BR112016000658 A2 BR 112016000658A2
Authority
BR
Brazil
Prior art keywords
pancreatin
pandreatic
usp
treating
high activity
Prior art date
Application number
BR112016000658A
Other languages
English (en)
Portuguese (pt)
Inventor
Perrett Stephen
Becker Robert
Boltri Luigi
Ghidorsi Luigi
Arzuffi Paola
Pironti Vincenza
Tota Michael
Ward William
Original Assignee
Allergan Pharmaceuticals International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016000658(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Pharmaceuticals International Limited filed Critical Allergan Pharmaceuticals International Limited
Publication of BR112016000658A2 publication Critical patent/BR112016000658A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112016000658A 2013-11-05 2014-11-05 pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática BR112016000658A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900092P 2013-11-05 2013-11-05
PCT/US2014/063984 WO2015069677A1 (en) 2013-11-05 2014-11-05 High potency pancreatin pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR112016000658A2 true BR112016000658A2 (pt) 2018-03-20

Family

ID=53042009

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016000658A BR112016000658A2 (pt) 2013-11-05 2014-11-05 pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática

Country Status (13)

Country Link
EP (2) EP3613429A1 (https=)
JP (1) JP2017500885A (https=)
KR (1) KR20170052520A (https=)
CN (1) CN106659773A (https=)
AU (1) AU2014346930A1 (https=)
BR (1) BR112016000658A2 (https=)
CA (1) CA2915671A1 (https=)
ES (1) ES2834483T3 (https=)
HK (1) HK1222325A1 (https=)
IL (3) IL243435B (https=)
MX (1) MX2016000480A (https=)
RU (1) RU2015155470A (https=)
WO (1) WO2015069677A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8246950B2 (en) 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
WO2009109856A2 (en) 2008-03-07 2009-09-11 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
CA2843556A1 (en) 2011-08-08 2013-02-14 Aptalis Pharma Ltd. Method for dissolution testing of solid compositions containing digestive enzymes
WO2015019198A2 (en) 2013-07-22 2015-02-12 Aptalis Pharma S.R.L. High potency pancreatin pharmaceutical compositions
MX2016001593A (es) 2013-08-09 2016-09-29 Allergan Pharmaceuticals Int Ltd Composicion de enzima digestiva adecuada para administracion enterica.
JP2017519490A (ja) * 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド 膵臓抽出物からのウイルス汚染の除去方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751330A (en) * 1952-08-27 1956-06-19 Armour & Co Use of a salt in the extraction slurry in recovering proteolytic enzymes from pancreas gland material
GB928654A (en) 1960-10-25 1963-06-12 Philips Nv Improvements in or relating to the production of pancreatin
US3168448A (en) 1963-01-07 1965-02-02 Wilson & Co Inc Process of preparing a lipolytic enzyme composition
DE2460334C3 (de) * 1974-12-20 1979-09-06 Hoechst Ag, 6000 Frankfurt Verfahren zur Gewinnung von Insulin und Pankreatin aus Schweinepankreas
EP0115023B1 (de) * 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
FR2603804B1 (fr) * 1986-09-17 1989-10-27 Jouveinal Sa Lipases et extraits lipasiques, leur procede de preparation et leur application en therapeutique
DE3927286C2 (de) * 1989-08-18 1997-07-24 Roehm Gmbh Wäßrige Enzym-Flüssigformulierungen
US6051220A (en) 1995-05-31 2000-04-18 Medzyme N.V. And Simon Lodewijk Scharpe Composition to improve digestibility and utilization of nutrients
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
DE19724845A1 (de) * 1996-08-28 1998-03-05 Solvay Pharm Gmbh Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
CA2419572A1 (en) * 2003-02-18 2004-08-18 Axcan Pharma Inc. High dosage protease formulation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
PT1809320E (pt) * 2004-10-14 2010-10-25 Altus Pharmaceuticals Inc Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US8246950B2 (en) * 2007-02-20 2012-08-21 Aptalis Pharma Limited Stable digestive enzyme compositions
RU2012142134A (ru) * 2010-03-19 2014-04-27 Апталис Фарма Кэнэда Инк. Желудочно-резистентные ферментные фармацевтические композиции
AU2011248293A1 (en) * 2010-05-03 2012-11-15 Eurand Pharmaceuticals Limited Micropellet compositions comprising pancreatin containing digestive enzyme mixtures
UA111726C2 (uk) * 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
CN103060297B (zh) * 2012-12-28 2014-06-25 青岛九龙生物医药有限公司 一种分离纯化胰蛋白酶的方法
CN103060296B (zh) * 2012-12-30 2014-05-21 青岛九龙生物医药有限公司 从动物胰脏中提取胰蛋白酶的方法
WO2015019198A2 (en) 2013-07-22 2015-02-12 Aptalis Pharma S.R.L. High potency pancreatin pharmaceutical compositions

Also Published As

Publication number Publication date
IL243435A0 (en) 2016-03-31
AU2014346930A1 (en) 2016-01-07
EP3613429A1 (en) 2020-02-26
MX2016000480A (es) 2016-10-21
HK1222325A1 (zh) 2017-06-30
EP3003360A4 (en) 2017-04-26
IL274583A (en) 2020-06-30
CA2915671A1 (en) 2015-05-14
IL243435B (en) 2020-06-30
WO2015069677A1 (en) 2015-05-14
JP2017500885A (ja) 2017-01-12
IL284419A (en) 2021-07-29
IL274583B (en) 2022-06-01
RU2015155470A3 (https=) 2018-09-10
CN106659773A (zh) 2017-05-10
RU2015155470A (ru) 2017-08-21
KR20170052520A (ko) 2017-05-12
EP3003360A1 (en) 2016-04-13
EP3003360B1 (en) 2020-10-07
ES2834483T3 (es) 2021-06-17

Similar Documents

Publication Publication Date Title
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
BR112017027411A2 (pt) inibidores de nadph oxidase 4
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
NZ716627A (en) Methods of treating behavioral symptoms of neurological and mental disorders
EA201592304A1 (ru) Способы лечения аутосомно-доминантой гиперхолестеринемии, ассоциированной с мутацией приобретения функции гена pcsk9
BR112018013151A2 (pt) alfa-glicosidase ácida aumentada para o tratamento da doença de pompe
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
BR112014026057A2 (pt) análogos limitados por anel como inibidores de arginase
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
BR112012027915A2 (pt) nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
ECSP13012852A (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a.
BR112022001161A2 (pt) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
BR112022015792A2 (pt) Inibidores de pad4 heterocíclicos
BR112014018379A8 (pt) Implante dental e processo para a produção de um implante dental
ECSP11011076A (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements